ArticleFrontiers in pediatrics2026
Majocchi's granuloma of the scalp caused by
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Majocchi's granuloma (MG) is a rare invasive dermatophytosis characterised by invasion of hair follicles and perifollicular granulomatous inflammation. Scalp involvement is uncommon, and Patient concerns and clinical findings: A 16-year-old boy with Crohn's disease treated with infliximab and azathioprine developed a painful inflammatory occipital scalp lesion with colliquation, pustulation, and regional lymphadenopathy shortly after a haircut-related injury. Diagnostic assessment: Initial antibacterial and antiviral therapy was ineffective. Dermatological assessment suggested an unusually severe tinea capitis/kerion-like presentation. Biopsy showed periodic acid-Schiff-positive fungal elements in the dermis with granulomatous suppurative inflammation. Culture yielded a weakly growing dermatophyte consistent with Therapeutic intervention and outcomes: Terbinafine 250 mg once daily failed to control disease progression. The patient improved after switching to itraconazole 200 mg twice daily, combined with repeated surgical debridement, topical antifungal treatment, and temporary interruption of immunosuppression. The lesion healed completely and hair regrowth was restored. Conclusion: This case highlights the need for early microbiological and histopathological assessment of severe scalp lesions in immunosuppressed patients, especially after skin-barrier disruption. It also raises awareness of possible dermatophyte transmission related to hairdressing and of a lack of clinical response to terbinafine in dermatophyte infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.